Business Context and Reporting Period
This Form 8-K Current Report was filed by InMed Pharmaceuticals Inc. on August 10, 2022, covering events occurring on August 8 and August 9, 2022. The company is incorporated in British Columbia, Canada, and its common shares trade on The Nasdaq Stock Market LLC under the symbol "INM". The filing primarily addresses changes to the Board of Directors.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The only financial figure disclosed relates to director compensation: the newly appointed director, Nicole Lemerond, is entitled to an annual retainer of $45,000, which includes committee participation fees.
Material Changes
- Resignation: Adam Cutler resigned from the Board of Directors, including his roles on the Nominating & Corporate Governance Committee and the Audit Committee, effective August 8, 2022. The resignation was due to personal reasons with no disagreement with the Company.
- Appointment: Nicole Lemerond was appointed as a director effective August 8, 2022, to fill the vacancy left by Mr. Cutler. She will serve on the Nominating & Corporate Governance Committee and the Audit Committee.
- Compensation: Ms. Lemerond received an annual retainer of $45,000 and was granted stock options to purchase 14,000 common shares.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, or management commentary regarding the company's business operations or financial future. No specific risks or contingencies were disclosed in this report, other than the standard disclosure that the press release furnished as Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the biographical background and qualifications of the new director, Nicole Lemerond, to assess her fit for the Audit and Nominating committees.
- Confirm the total number of outstanding stock options granted to Ms. Lemerond (14,000 shares) and their terms.
- Review the press release (Exhibit 99.1) for any additional context regarding the board composition changes.
- Note that this filing does not provide updated financial performance data; refer to the most recent 10-K or 10-Q for financial metrics.